COEPTIS THERAPEUTICS INC.
COEPTIS THERAPEUTICS INC. (NDYN): 4 pipeline candidates · ~21 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.4 months
D/E 0.67 · 0% dilution
Lead: Preclinical
4 candidates
N/A
N/A
A transparent, data-derived signal for COEPTIS THERAPEUTICS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7.4M
Quarterly Burn
$1.0M
Runway
21.4 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| cd38-diagnostic | Preclinical |
| cd38-gear-nk | Preclinical |
| cpt60621 | Preclinical |
| stat-201 | Preclinical |
Frequently asked questions
How many drug candidates are in COEPTIS THERAPEUTICS INC.'s pipeline?
COEPTIS THERAPEUTICS INC. (NDYN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is COEPTIS THERAPEUTICS INC.'s lead drug candidate?
COEPTIS THERAPEUTICS INC.'s most advanced tracked candidate is cd38-diagnostic (Preclinical) for B cell malignancies with high CD38 expression, including multiple myeloma.
What is COEPTIS THERAPEUTICS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, COEPTIS THERAPEUTICS INC. has approximately 21.4 months of cash runway.
Get the full picture on COEPTIS THERAPEUTICS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.